126610-134x178.jpg

November/December 2012

Volume 15, Issue 7

 

 

 

Browse other issues »Subscribe to our print issues »

Articles in this Issue

  • Particle Identification and Material Characterization with Raman Microspectroscopic Technique...

    Dr. Xiaolin Cao, Ph.D.
    Raman spectroscopic technique has made tremendous progress in the past decade with respect to its sensitivity, functionality and versatility. Its applications in pharmaceutical industry have been expanded markedly
  • Improved Analytical Recovery by Taking into Account Sample Matrix and Chromatographic Instrumentation

    Jianhua Li, Jenny Lee, Murty Varanasi, Ph.D., Kang Ping Xiao, Ph.D.
    Developing a robust analytical method for pharmaceutical products is always challenging. A lot of effort has been devoted to chromatographic separations, column selections, and quick analysis turnaround time. On the other hand, less attention has been paid to sample preparation and/or to the subtle differences in various chromatographic instrumentation. Matrix effect seems to be more of a concern in bioanalytical samples or for LC-MS studies [1].
  • Implementing Nanotechnology and Novel Drug Delivery Systems to Improve Dissolution and Solubilization

    Clare Hoskins, Woei Ping Cheng
    Drug efficacy and bioavailability are largely dependent on drug physicochemical properties such as water solubility, pKa and Log P. Today it is widely recognized that up to 60% of new drugs in the developmental stage are water insoluble [1] and this presents a major challenge to the pharmaceutical industry. For drugs to be administered intravenously, drugs formulated as aqueous-based injections are most desirable. Thus drug aqueous solubility is a prerequisite [2]. For oral drug delivery, drugs must be able to dissolve in the aqueous gastrointestinal fluid before absorption can take place in the gastrointestinal tract (GIT) [3]. Therefore, for drugs which have high permeability but with poor solubility (Class II according to Biopharmaceutics Classification System), rate of dissolution is a major rate limiting step for the absorption of these drugs via oral administration. As a result, this undesirable property often leads to poor oral bioavailability and erratic GIT absorption.
  • The Use of Thorough Microbial Impact Assessment to Control Bioburden on a Particular Process...

    Lada Laenen, Ph.D., Ruth Daniels, Ph.D., Liesbeth Bouchet, Koenraad Swinnen
    Genzyme is a global biopharmaceutical company with 7 major approved products and serving patients in more than 100 countries. Genzyme has substantial experience in medical, clinical and regulatory affairs. In April 2011, Genzyme became a wholly owned company of Sanofi, one of the world’s largest pharmaceutical companies. Sanofi’s portfolio of products includes: prescription medicines, vaccines, generics, consumer health care, and animal health. Genzyme is Sanofi’s global center of excellence in rare diseases and multiple sclerosis (MS). Genzyme’ major marketed therapeutic products: specific recombinant enzymes for the treatment of the rare, genetic, lysosomal storage disorders (Gaucher, Fabry, MPSI and Pompe disease), a recombinant protein hormone for use in the management of thyroid cancer and a recently approved oral therapy for Multiple Sclerosis (MS). Genzyme has another late stage product for the treatment of MS and an innovative, late stage product in the field of familial hypercholesterolemia.
  • Troubleshooting During the Manufacture of Lyophilized Drug Product- Being Prepared for the...

    Shouvik Roy, Ph.D., Christian Ruitberg, Ananth Sethuraman, Ph.D.
    Lyophilization is widely used for pharmaceuticals / biopharmaceuticals to improve stability and provide adequate shelf life. In spite of wellestablished records of process development [1-8] scale-up/tech-transfer, [9-16] and validation [17] of optimized lyophilization process, deviations to the validated process still occur during commercial manufacturing. Each process deviation requires an assessment of the impact to product quality and stability.
  • The Importance of Quality Control in the Production of Parenteral Drugs

    Cara N. Wilder, Ph.D.,, Elizabeth Kerrigan
    Microbial contamination of parenteral products is one of the most serious issues currently facing the pharmaceutical industry. Injectable drugs, which are administered directly into the circulatory system, bypass a number of innate human immune defenses associated with the gastrointestinal system. Therefore, to ensure the sterility of each of these products prior to patient administration, pharmaceutical companies must adhere to strict government regulations regarding quality control. Maintaining and following a robust quality control program is integral to quality standards and meeting regulatory requirements.
  • Interview with Catalent-Introducing the Applied Drug Delivery Institute

    Kurt Nielsen
    The Catalent Applied Drug Delivery Institute brings together the knowledge of the world’s leading experts in drug development, delivery and formulation—within Catalent, the industry and academia. This collaborative approach is designed to help bring better treatments to market by advancing the development and adoption of applied drug delivery technologies.
  • Discriminant Analysis of Raw Materials Using Near-Infrared Spectroscopy

    Robert Mattes
    Near-infrared spectroscopy (NIRS) is an analytical technique based on absorption measured in the near-infrared region of the electromagnetic spectrum that is between the visible and the mid-infrared regions. The fundamental absorption bands of functional groups occur in the mid-infrared and are very strong. The overtone absorptions of these fundamental bands occur in the near-infrared (NIR) spectral region and allow direct measurement without sample preparation due to the relative weakness of absorption. The OH, CH, NH and SH bonds have the strongest overtone absorbance in the NIR region. [1]
  • Challenges and Opportunities in Oral Formulation Development

    Dr. Shaukat Ali, Dr. Karl Kolter
    Over 60% of new chemical entities that are poorly soluble qualify either as BCS Class II or Class IV and they provide challenges as well as opportunities to scientists working in formulation development [1]. The conventional solubilization approaches such as physical modifications of drug crystals (surface alteration of API, micronization or micro-milling) usually lead to a limited dissolution and solubility enhancement, but when developing a medium or high dosed formulation, the non-conventional formulation approaches are often required particularly when dealing with almost water-insoluble compounds usually characterized by a high melting point and/or very high lipophilicity [2].
  • The Benefits of a High-Performance, Handheld Raman Spectrometer for the Rapid Identification...

    Dawn Yang, Robert Thomas
    In recent years, Raman Spectroscopy has gained a reputation in market segments that require the rapid identification of unknown compounds, such as the testing of high purity chemicals, measurement of pharmaceutical ingredients and the characterization of polymer materials. The reasons behind this surge of interest, is that modern Raman instrumentation using intelligent decision-making software and on-board spectral libraries, is an ideal technique for molecular fingerprinting purposes.
  • Validation of an Amplified-ATP Bioluminescence Method for the Rapid Detection of Contamination...

    Thomas H. Chrzanowski, Ronald L. Smith
    The equivalence of two test methods that detect microbiological contamination was evaluated by comparing the rate of positive and negative results obtained from identical samples. The methods were a rapid, Amplified-ATP bioluminescence (ATP+) method and the compendial plate count method. The study measured the degree to which the methods agreed when performed repeatedly on multiple lots of the same product.
  • Disposable Freeze Systems in the Pharmaceutical Industry

    Adam Goldstein, Michael Pohlscheidt, Jacqueline Loesch, Kellen Mazzarella, Boris Bieger, Philippe Lam, Joey Teshima
    Recombinant DNA technology has enabled the industrial production of monoclonal antibodies and recombinant proteins for targeted treatments of several diseases like cancer, viral infections, and so on. Therefore, the production of biotherapeutics is of increasing importance for the pharmaceutical industry. Recently, a large number of monoclonal antibodies and therapeutic proteins have been approved and will be the major source of revenue for the industry in upcoming years [1-5]. The expression system of choice for the production of complex recombinant proteins and antibodies are mammalian cells cultivated in suspension [6-9]. Manufacturing scales up to 25 m3 operated in a batch, fed batch or repeated batch mode are state of the art in the industry. Following the cell culture process, a sequence of chromatography, filtration and concentration steps are performed and the purified bulk drug substance is frozen for improved long-term stability [10, 11] - a typical antibody production process is shown in Shukla and Thömmes 2010 [12].
  • <<
  • >>